TR202018115A2 - Covid 19 hastaliğinin tani ve i̇zlemi̇nde t hücre yanitinin taki̇bi̇ne ai̇t laboratuvar ve kli̇ni̇k test yöntemi̇ - Google Patents
Covid 19 hastaliğinin tani ve i̇zlemi̇nde t hücre yanitinin taki̇bi̇ne ai̇t laboratuvar ve kli̇ni̇k test yöntemi̇ Download PDFInfo
- Publication number
- TR202018115A2 TR202018115A2 TR2020/18115A TR202018115A TR202018115A2 TR 202018115 A2 TR202018115 A2 TR 202018115A2 TR 2020/18115 A TR2020/18115 A TR 2020/18115A TR 202018115 A TR202018115 A TR 202018115A TR 202018115 A2 TR202018115 A2 TR 202018115A2
- Authority
- TR
- Turkey
- Prior art keywords
- diagnosis
- laboratory
- test method
- clinical test
- covid
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 238000010998 test method Methods 0.000 title abstract 2
- 208000025721 COVID-19 Diseases 0.000 title 1
- 230000005867 T cell response Effects 0.000 title 1
- 238000012544 monitoring process Methods 0.000 title 1
- 241000700605 Viruses Species 0.000 abstract 2
- 241001678559 COVID-19 virus Species 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000005875 antibody response Effects 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
Abstract
Buluş, SARS-CoV-2 dahil antikor yanıtının yeterli olmadığı viral enfeksiyonlarda kişinin virüsle karşılaşıp karşılaşmadığı ve/veya virüse karşı immünite geliştirip geliştirmediğinin gösterilmesi amacıyla tanı ve tedaviye yanıta yönelik laboratuvar ve klinik test yöntemi ile ilgilidir.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2020/18115A TR202018115A2 (tr) | 2020-11-12 | 2020-11-12 | Covid 19 hastaliğinin tani ve i̇zlemi̇nde t hücre yanitinin taki̇bi̇ne ai̇t laboratuvar ve kli̇ni̇k test yöntemi̇ |
PCT/TR2020/051311 WO2022103351A1 (en) | 2020-11-12 | 2020-12-16 | Laboratory and clinical test method for the follow-up of t cell response in the diagnosis and monitoring of covid 19 disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2020/18115A TR202018115A2 (tr) | 2020-11-12 | 2020-11-12 | Covid 19 hastaliğinin tani ve i̇zlemi̇nde t hücre yanitinin taki̇bi̇ne ai̇t laboratuvar ve kli̇ni̇k test yöntemi̇ |
Publications (1)
Publication Number | Publication Date |
---|---|
TR202018115A2 true TR202018115A2 (tr) | 2021-05-21 |
Family
ID=77515631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2020/18115A TR202018115A2 (tr) | 2020-11-12 | 2020-11-12 | Covid 19 hastaliğinin tani ve i̇zlemi̇nde t hücre yanitinin taki̇bi̇ne ai̇t laboratuvar ve kli̇ni̇k test yöntemi̇ |
Country Status (2)
Country | Link |
---|---|
TR (1) | TR202018115A2 (tr) |
WO (1) | WO2022103351A1 (tr) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015035260A1 (en) * | 2013-09-06 | 2015-03-12 | Theranos, Inc. | Systems and methods for detecting infectious diseases |
-
2020
- 2020-11-12 TR TR2020/18115A patent/TR202018115A2/tr unknown
- 2020-12-16 WO PCT/TR2020/051311 patent/WO2022103351A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2022103351A1 (en) | 2022-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Azzi et al. | Rapid Salivary Test suitable for a mass screening program to detect SARS-CoV-2: A diagnostic accuracy study | |
Crameri et al. | Experimental infection and response to rechallenge of alpacas with Middle East respiratory syndrome coronavirus | |
Bonnet et al. | Overview of the diagnostic methods used in the field for human African trypanosomiasis: what could change in the next years? | |
Greigert et al. | When biology supports clinical diagnosis: review of techniques to diagnose ocular toxoplasmosis | |
Sharma et al. | Rapid detection of SARS‐CoV‐2 in saliva: can an endodontist take the lead in point‐of‐care COVID‐19 testing? | |
Poirot et al. | Detection of avian influenza A (H7N2) virus infection among animal shelter workers using a novel serological approach—New York City, 2016–2017 | |
Dung et al. | Seroprevalence survey of avian influenza A (H5N1) among live poultry market workers in northern Viet Nam, 2011 | |
Taylor et al. | No evidence of prolonged Hendra virus shedding by 2 patients, Australia | |
TR202018115A2 (tr) | Covid 19 hastaliğinin tani ve i̇zlemi̇nde t hücre yanitinin taki̇bi̇ne ai̇t laboratuvar ve kli̇ni̇k test yöntemi̇ | |
Mahapatra et al. | NS1 antigen capture ELISA an effective method for diagnosis of early dengue infection-Report of an outbreak at Angul district, Odisha, India | |
ES2637200T3 (es) | Procedimiento para el diagnóstico in vitro y/o monitorización de terapia in vitro de infecciones | |
Eruznannx et al. | Inapparent infections of brown trout with VHS-virus | |
Otani et al. | Varicella zoster virus antibody detection: A comparison of four commonly used techniques | |
Kang et al. | The emerging epidemics in recent: mpox | |
Roebroek et al. | Aseptic meningitis caused by the lymphocytic choriomeningitis virus | |
Al-zobaei | Comparison between haemagglutination inhibition and complement fixation tests in detecting antibodies responses following influenza viral infection | |
Tarro | Cell Immunity, Air Transmission and Therapy Approach for COVID-19 | |
Salustiano et al. | Comparison among the BED capture enzyme immunoassay test and AxSYM avidity index assay for determining recent HIV infection and incidence in two Voluntary Counselling and Testing Centres in Northeast Brazil | |
Gupta et al. | Role of Treponema pallidum hemagglutination assay for diagnosis of syphilis in low titers of VDRL-reactive sera: A prospective study from a large tertiary care center of East Delhi | |
Banović et al. | Unexpected TBEV Seropositivity in Serbian Patients Who Recovered from Viral Meningitis and Encephalitis. Pathogens 2022, 11, 371 | |
RU2702011C1 (ru) | Способ диагностики инфекционных, аллергических, аутоиммунных и онкологических заболеваний | |
Pariani et al. | How multiplex testing approach to respiratory viruses detection can enhance influenza surveillance | |
Daste et al. | Which healthcare workers are at greatest risk of testing positive for COVID-19 IgG antibodies? | |
RU2239840C1 (ru) | Способ оценки активности хронической рецидивирующей герпетической инфекции | |
Majeed | Diagnosis of HCV infection in renal chronic infection patients by using ELISA and RT-PCR in Tikrit City |